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ABSTRACT	 	
A simple, Accurate, precise method was developed for the simultaneous estimation of the Sofosbuvir 
and Ledipasvir in Tablet dosage form. Chromatogram was run through Std Discovery C8 150 x 4.6 mm, 
5µ. Mobile phase containing Buffer 0.1% OPA: Acetonitrile taken in the ratio 60:40 was pumped 
through column at a flow rate of 1 ml/min. Buffer used in this method was 0.1% OPA buffer. Tempera-
ture was maintained at 30°C. Optimized wavelength selected was 260 nm. Retention time of Sofosbuvir 
and Ledipasvir were found to be 2.367 min and 3.436 min. %RSD of the Sofosbuvir and Ledipasvir 
were and found to be 0.6 and 0.5 respectively. %Recovery was obtained as 99.61% and 99.80% for 
Sofosbuvir and Ledipasvir respectively. LOD, LOQ values obtained from regression equations of Sofos-
buvir and Ledipasvir were 0.67, 2.02 and 0.70, 2.12 respectively. Regression equation of Sofosbuvir is 
y = 4266.x + 7700, and y = 4861.x + 2656.of Ledipasvir. Retention times were decreased and run time 
was decreased, so the method developed was simple and economical that can be adopted in regular 
Quality control test in Industries.	
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INTRODUCTION	Development	of		the		simple		and		reproducible	ana-lytical	 methods	 for	 estimation	 of	 multi	 component	drugs	is	very	important	part	of	quality	control	and	for	
social		awareness		which		was		established		in		present	work.		
 
Figure 1: chemical structure of sofosbuvir Sofosbuvir[1-3]	is	a	prodrug	nucleotide	analog	used	as	part	of	combination	therapy	to	treat	hepatitis	C	virus	(HCV)	 infection	 or	 to	 treat	 co-infection	 of	 HIV	 and	HCV.	After	metabolism	to	the	active	antiviral	agent	2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphos-phate	(also	known	as	GS-461203),	 the	triphosphate	serves	as	a	defective	substrate	for	the	NS5B	protein,	an	 RNA-dependent	 RNA	 polymerase	 required	 for	replication	 of	 viral	 RNA.	 More	 recently,	 sofosbuvir	has	become	available	as	a	fixed	dose	drug	combina-tion	product	with	ledipasvir[1-3]	(trade	name	Harvoni	
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)	used	for	the	treatment	of	chronic	Hepatitis	C,	an	in-fectious	liver	disease	caused	by	infection	with	Hepa-titis	C	Virus	(HCV).	Approved	in	October	2014	by	the	FDA,	ledipasvir	and	sofosbuvir	are	direct-acting	anti-viral	agents	indicated	for	the	treatment	of	HCV	geno-type	1	with	or	without	cirrhosis.	Ledipasvir,	 previously	 known	 as	 GS-5885,	 is	 an	inhibitor	of	the	Hepatitis	C	Virus	(HCV)	NS5A	protein	required	 for	 viral	 RNA	 replication	 and	 assembly	 of	HCV	virions.	Although	its	exact	mechanism	of	action	is	 unknown,	 it	 is	 postulated	 to	 prevent	 hyper	phosphorylation	of	NS5A	which	is	required	for	viral	production.	It	is	effective	against	genotypes	1a,	1b,	4a,	and	5a	and	with	a	lesser	activity	against	genotypes	2a	and	3a	of	HCV.	Ledipasvir	is	available	as	a	fixed	dose	drug	 combination	 product	 with	 sofosbuvir	(tradename	 Harvoni)	 used	 for	 the	 treatment	 of	chronic	Hepatitis	C,	an	infectious	liver	disease	caused	by	infection	with	Hepatitis	C	Virus	(HCV).	Approved	in	October	2014	by	the	FDA,		
 
Figure 2: Chemical structure of ledipasvir	
MATERIALS	AND	METHODS	
Materials:	 Sofosbuvir	 and	 Ledipasvir	 pure	 drugs	(API),	Combination	Sofosbuvir	and	Ledipasvir	tablets	(Harvoni),	 Distilled	 water,	 Acetonitrile,	 Phosphate	buffer,	Methanol,	Potassium	dihydrogen	ortho	phos-phate	 buffer,	 Ortho-phosphoric	 acid.	 All	 the	 above	chemicals	and	solvents	are	from	Rankem.3-4	
HPLC	method	
Instrument:	 UV-VIS	 spectrophotometer	 PG	Instruments	T60	with	special	bandwidth	of	2	mm	and	10mm	and	matched	quartz	cells	 integrated	with	UV	win	6	Software	was	used	for	measuring	absorbances	of	 Sofosbuvir	 and	 Ledipasvir	 	 solutions	 having	universal		loop	injector	of	injection	capacity	20μL[4-6].	The	column	used	was		Discovery	C18	(4.6	x	250mm,	5µm)	 at	 ambient	 temperature.	 Different	 mobile	phases	 were	 tested	 	 in	 	 order	 	 to	 	 find	 	 the	 	 best		conditions,	 	 for	 separating	 both	 the	 drugs	simultaneously.	 Optimised	 Chromatographic	conditions	 The	 	 mobile	 	 phase	 	 having	 	 60%	 OPA	(0.1%):	40%	Acetonitrile	was	selected	because	it	was	found	that	it	ideally	resolve	the	peaks	with	retention	time	 (RT)	 2.380	min	 and	 3.449	min	 for	 Sofosbuvir	and	 Ledipasvir	 respectively[7-8].	 	 Wavelength	 	 was		selected	 	by	 scanning	 	 all	 	 standard	 	drugs	 	 over	 	 a		wide		range		of	wavelength	200nm	to	350nm.	Both	the	
components	 showed	 reasonably	 good	 response	 at	260	nm.	
Methods:	
Diluent:	 Based	 up	 on	 the	 solubility	 of	 the	 drugs,	diluent	was	selected,	Acetonitrile	and	Water	taken	in	the	ratio	of	50:50	
Preparation	 of	 Standard	 stock	 solutions:	Accurately	 weighed	 40mg	 of	 Sofosbuvir,	 9mg	 of	Ledipasvir	 and	 transferred	 to	 25ml	 &	 25ml	volumetric	flasks	and	3/4th	of	diluents	was	added	to	these	flask	and	sonicated	for	10	minutes.	Flask	were	made	up	with	diluents	and	labelled	as	Standard	stock	solution.	 (1600µg/ml	 of	 Sofosbuvir	 and	 360µg/ml	Ledipasvir)	
Preparation	 of	 Standard	 working	 solutions	
(100%	solution):	1ml	from	each	stock	solution	was	pipetted	out	and	taken	into	a	10ml	volumetric	flask	and	made	up	with	diluent.	(160µg/ml	of	Sofosbuvir	and	36µg/ml	of	Ledipasvir).	
Preparation	 of	 Sample	 stock	 solutions:	5	 tablets	were	weighed	and	the	average	weight	of	each	tablet	was	calculated,	then	the	weight	equivalent	to	1	tablet	was	transferred	into	a	50ml	volumetric	flask,	50ml	of	diluents	was	added	and	sonicated	for	25	min,	further	the	volume	was	made	up	with	diluent	and	filtered	by	HPLC	filters	(800µg/ml	of	Sofosbuvir	and	1800µg/ml	of	Ledipasvir)	
Preparation	of	Sample	working	solutions	(100%	
solution):	0.2ml	of	filtered	sample	stock	solution	was	transferred	 to	 10ml	 volumetric	 flask	 and	 made	 up	with	diluent.(160µg/ml	of	Sofosbuvir	and	36µg/ml	of	Ledipasvir).	
Preparation	of	buffer:	
0.1%OPA	Buffer:	1ml	of	ortho	phosphoric	acid	was	diluted	to	1000ml	with	HPLC	grade	water.	
Typical	Chromatogram	Retention	 times	 of	 Sofosbuvir	 and	 Ledipasvir	were	2.369	min	 and	 3.436	min	 respectively.	We	 did	 not	found	and	interfering	peaks	in	blank	and	placebo	at	retention	times	of	these	drugs	in	this	method.	So	this	method	was	said	to	be	specific.	
 
Figure 3: Typical Chromatogram of Sofosbuvir and 
Ledipasvir 
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Linearity:	 Six	 linear	 concentrations	 of	 Sofosbuvir	(40-240µg/ml)	 and	 Ledipasvir	 (9-54µg/ml)	 were	injected	 in	a	duplicate	manner.	Average	areas	were	mentioned	 above	 and	 linearity	 equations	 obtained	for	 Sofosbuvir	 was	 y	 =	 4266.x	 +	 7700and	 of	Ledipasvir	 was	 y	 =4861.x	 +	 2656Correlation	coefficient	obtained	was	0.999	for	the	two	drug.	
Table 3: Linearity of Sofosbuvir and Ledipasvir  
S.	
NO	
Sofosbuvir	 Ledipasvir	
Conc	
(µg/ml)	 Area	
Conc	
(µg/ml)	 Area	1	 0	 0	 0	 0	2	 40	 193238	 9	 48575	3	 80	 346154	 18	 92565	4	 120	 523238	 27	 135642	5	 160	 680185	 36	 174059	6	 200	 853929	 45	 219015	
 
Figure 4: Calibration curve of sofosbuvir 
 
Figure 5: calibration curve of ledipasvir 
System	suitability	parameters:	The	system	suitability	parameters	were	determined	by	 preparing	 standard	 solutions	 of	 Sofosbuvir	(160ppm)	and	Ledipasvir	(36ppm)	and	the	solutions	were	injected	six	times	and	the	parameters	like	peak	tailing,	 resolution	 and	 USP	 plate	 count	 were	determined.	The	 %	 RSD	 for	 the	 area	 of	 six	 standard	 injections	results	should	not	be	more	than	2%.	
Specificity:	 Checking	 of	 the	 interference	 in	 the	optimized	 method.	 We	 should	 not	 find	 interfering	peaks	in	blank	and	placebo	at	retention	times	of	these	drugs	in	this	method.	So	this	method	was	said	to	be	specific.	
Precision:	
Preparation	 of	 Standard	 working	 solutions	
(100%	solution):	1ml	from	each	stock	solution	was	pipetted	out	and	taken	into	a	10ml	volumetric	flask	
Table 1: System suitability parameters for Sofosbuvir and Ledipasvir 
S.no Sofosbuvir Ledipasvir  
Inj RT (min) USP Plate Count Tailing RT (min) USP Plate Count Tailing Resolution 
1 2.366 5341 1.08 3.434 9522 1.09 7.5 
2 2.367 5497 1.09 3.436 9659 1.09 7.6 
3 2.367 5685 1.08 3.436 9776 1.08 7.5 
4 2.369 5082 1.04 3.436 9731 1.10 7.5 
5 2.369 5104 1.03 3.438 10083 1.09 7.6 
6 2.372 5095 1.03 3.447 9852 1.05 7.7 
Table 2: Accuracy table of Sofosbuvir and Ledipasvir 
 Sofosbuvir Ledipasvir 
% Level 
Amount 
Spiked 
(μg/mL) 
Amount re-
covered 
(μg/mL) 
% Re-
covery 
Amount 
Spiked 
(μg/mL) 
Amount re-
covered 
(μg/mL) 
% Re-
covery 
50% 
80 79.779 99.72 18 17.986 99.92 
80 79.543 99.43 18 17.979 99.88 
80 79.306 99.13 18 17.949 99.72 
100% 
160 159.392 99.62 36 35.902 99.73 
160 159.779 99.86 36 35.915 99.76 
160 159.761 99.85 36 35.889 99.69 
150% 
240 239.079 99.62 54 53.976 99.95 
240 239.099 99.62 54 53.796 99.62 
240 239.0872 99.62 54 53.959 99.92 
Mean %Re-
covery 99.61% 99.80% 
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and	made	up	with	diluent.	(160µg/ml	of	Sofosbuvir	and	36µg/ml	of	Ledipasvir).	
Repeatability:	 Multiple	 sampling	 from	 a	 sample	stock	 solution	 was	 done	 and	 six	 working	 sample	solutions	 of	 same	 concentrations	 were	 prepared,	each	 injection	 from	 each	 working	 sample	 solution	was	given	and	obtained	areas	were	mentioned	in	the	above	table.	Average	area,	standard	deviation	and	%	RSD	were	calculated	 for	 two	drugs	and	obtained	as	0.5%	 and	 0.6%	 respectively	 for	 Sofosbuvir	 and	Ledipasvir.	As	the	limit	of	Precision	was	less	than	“2”	the	system	precision	was	passed	in	this	method.	
Accuracy:	
Preparation	 of	 50%	 Spiked	 Solution:	 0.5ml	 of	sample	 stock	 solution	 was	 taken	 into	 a	 10ml	volumetric	 flask,	 to	 that	 1.0ml	 from	 each	 standard	stock	solution	was	pipetted	out,	and	made	up	to	the	mark	with	diluent.	
Preparation	 of	 100%	 Spiked	 Solution:	 1.0ml	 of	sample	 stock	 solution	 was	 taken	 into	 a	 10ml	volumetric	 flask,	 to	 that	 1.0ml	 from	 each	 standard	stock	solution	was	pipetted	out,	and	made	up	to	the	mark	with	diluent.	
Preparation	 of	 150%	 Spiked	 Solution:	 1.5ml	 of	sample	 stock	 solution	 was	 taken	 into	 a	 10ml	volumetric	 flask,	 to	 that	 1.0ml	 from	 each	 standard	stock	solution	was	pipetted	out,	and	made	up	to	the	mark	with	diluent.	
Accuracy:	 Three	 levels	 of	 Accuracy	 samples	 were	prepared	 by	 standard	 addition	 method.	 Triplicate	injections	were	given	for	each	level	of	accuracy	and	mean	 %Recovery	 was	 obtained	 as	 99.61%	 and	99.80%	for	Sofosbuvir	and	Ledipasvir	respectively[9-10].	
Table 4: Sensitivity table of Sofosbuvir and Ledipasvir 
Molecule	 LOD	 LOQ	Sofosbuvir	 0.67	 2.02	Ledipasvir	 0.70	 2.12	
Precision:	Multiple	 sampling	 from	 a	 sample	 stock	solution	was	done	and	six	working	sample	solutions	of	same	concentrations	were	prepared,	each	injection	from	each	working	sample	solution	was	given	on	the	next	 day	 of	 the	 sample	 preparation	 and	 obtained	areas	 were	 mentioned	 in	 the	 above	 table.	 Average	area,	standard	deviation	and	%	RSD	were	calculated	for	 two	 drugs	 and	 obtained	 as	 0.5%	 and	 0.6%	respectively	 for	 Sofosbuvir	 and	 Ledipasvir.	 As	 the	limit	 of	 Precision[11]	 was	 less	 than	 “2”,	 the	 system	precision	was	passed	in	this	method.	
Table 5: System precision table of Sofosbuvir and 
Ledipasvir 
S.	No Area	of	Sofos-buvir 
Area	of	Ledipas-
vir 
1. 698943 177127 
2. 695463 176673 
3. 693621 177445 
4. 704923 179081 
5. 698452 176591 
6. 693668 177154 
Mean 697512 177345 
S.D 4288.8 908.6 
%RSD 0.6 0.5 
Table 6: Intermediate precision table of Sofosbuvir 
and Ledipasvir 
S.	No Area	of	Sofos-buvir 
Area	of	Ledipas-
vir 
1. 695241 176978 
2. 695200 176075 
3. 694259 176873 
4. 694723 176902 
5. 697754 176596 
6. 696181 177083 
Mean 695560 176751 
S.D 1250.9 368.9 
%RSD 0.2 0.2 
Robustness:	Small	deliberate	changes	in	method	like	Flow	rate,	mobile	phase	 ratio,	 and	 temperature	are	made	 but	 there	 were	 no	 recognized	 change	 in	 the	result	and	are	within	range	as	per	ICH	Guide	lines.	
Table 7: Robustness data for Sofosbuvir and Ledipas-
vir 
S.no Condition %RSD	of	Sofosbuvir 
%RSD	of	
Ledipasvir 
1 Flow	rate	(-)	0.9ml/min 0.5 0.4 
2 Flow	rate	(+)	1.1ml/min 0.5 0.7 
3 Mobile	phase	(-)	65B:35A 0.5 0.4 
4 Mobile	phase	(+)	55B:45A 0.5 0.5 
5 Temperature	(-)	25°C 0.3 0.3 
6 Temperature	(+)	35°C 0.1 0.1 Robustness	conditions	like	Flow	minus	(0.9ml/min),	Flow	plus	(1.1ml/min),	mobile	phase	minus,	mobile	phase	 plus,	 temperature	 minus	 (25°C)	 and	temperature	plus(35°C)	was	maintained	and	samples	were	injected	in	duplicate	manner.	System	suitability	parameters	 were	 not	 much	 effected	 and	 all	 the	parameters	were	passed.	%RSD	was	within	the	limit.	Robustness	conditions	like	Flow	minus	(0.9ml/min),	Flow	 plus	 (1.1ml/min),	 mobile	 phase	 minus	(65B:35A),	 mobile	 phase	 plus	 (55B:45A),	temperature	 minus	 (25°C)	 and	 temperature	plus(35°C)	 was	 maintained	 and	 samples	 were	injected	 in	 duplicate	 manner.	 System	 suitability	parameters	 were	 not	 much	 affected	 and	 all	 the	parameters	were	passed.	%RSD	was	within	the	limit.		
LOD	 sample	 Preparation:	 0.25ml	 each	 from	 two	standard	 stock	 solutions	 was	 pipetted	 out	 and	transferred	 to	 two	 separate	 10ml	 volumetric	 flasks	
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and	made	up	with	diluents.	From	the	above	solutions	0.1ml	 each	 of	 Sofosbuvir,	 Ledipasvir,	 solutions	respectively	 were	 transferred	 to	 10ml	 volumetric	flasks	and	made	up	with	the	same	diluents	
LOQ	 sample	 Preparation:	 0.25ml	 each	 from	 two	standard	 stock	 solutions	 was	 pipetted	 out	 and	transferred	 to	 two	 separate	 10ml	 volumetric	 flask	and	made	up	with	diluent.	From	the	above	solutions	0.3ml	 each	 of	 Sofosbuvir,	 Ledipasvir,	 solutions	respectively	 were	 transferred	 to	 10ml	 volumetric	flasks	and	made	up	with	the	same	diluent.	
Assay:	 Radha	 Kishna	 Pharmaceuticals,	(Hepcvir	L)bearing	 the	 label	 claim	 Sofosbuvir	 400mg,	Ledipasvir	 90mg.Assay	 was	 performed	 with	 the	above	 formulation.	Average	%	Assay	 for	Sofosbuvir	and	 Ledipasvir	 obtained	 was	 99.32	 and	 98.47%	respectively.	
Table 8: Assay Data of Sofosbuvir 
S.no	 Standard	Area	
Sample	
area	
%	
Assay	
1	 698943	 695241	 99.28	
2	 695463	 695200	 99.27	
3	 693621	 694259	 99.14	
4	 704923	 694723	 99.20	
5	 698452	 697754	 99.63	
6	 693668	 696181	 99.41	
Avg	 697512	 695560	 99.32	
Stdev	 4288.8	 1250.9	 0.18	
%RSD	 0.6	 0.2	 0.18	
Table 9: Assay Data of Ledipasvir 
S.no	 Standard	Area	
Sample	
area	
%	
Assay	
1	 177127	 176978	 99.59	
2	 176673	 176075	 99.09	
3	 177445	 176873	 99.53	
4	 179081	 176902	 99.55	
5	 176591	 176596	 99.38	
6	 177154	 177083	 99.65	
Avg	 177345	 176751	 99.47	
Stdev	 908.6	 368.9	 0.2	
%RSD	 0.5	 0.2	 0.2	
Degradation	 studies:	 Degradation	 studies	 were	performed	 with	 the	 formulation	 and	 the	 degraded	samples	were	injected.	Assay	of	the	injected	samples	was	calculated	and	all	the	samples	passed	the	limits	of	degradation.	
Oxidation:	 To	 1	ml	 of	 stock	 solution	 of	 Sofosbuvir	and	 Ledipasvir,	 1	 ml	 of	 20%	 hydrogen	 peroxide	(H2O2)	was	added	separately.	The	solutions	we	are	kept	 for	 30	 min	 at	 600c.	 For	 HPLC	 study,	 there	solution	 was	 diluted	 to	 obtain	 160µg/ml&36µg/ml	solution	 and10µlwere	 injected	 into	 the	 system	 and	the	 chromatograms	 were	 recorded	 to	 assess	 the	stability	of	sample.	
Acid	Degradation			Studies:	To	1ml	of	stock	solution	Sofosbuvir	 and	 Ledipasvir,	 1ml	 of	 2N	 Hydrochloric	acid	was	added	and	refluxed	for	30mins	at	600c.The	
resultant	solution	was		diluted	to	obtain	160µg/ml	&	36µg/ml	 solution	 and	 10µl	 solutions	were	 injected	into	 the	 system	 and	 the	 chromatograms	 were	recorded	to		assess	the	stability	of	sample.	
Alkali	 Degradation	 Studies:	 To	 1	 ml	 of	 stock	solution	Sofosbuvir	and	Ledipasvir,	1ml	of	2N	sodium	hydroxide	was	added	and	refluxed	for	30mins	at	600c.	There	 sultant	 solution	 was	 diluted	 to	 obtain	160µg/ml	&	36µg/ml	solution	and	10µl	were	injected	into	 the	 system	 and	 the	 chromatograms	 were	recorded	to	assess	the	stability	of	sample.	
Dry	Heat	Degradation	Studies:	The	standard	drug	solution	was	 placed	 inovenat105°C	 for1hr	 to	 study	dry	heat	degradation.	For	HPLC	study,	the	resultant	solution	was	diluted	to	160µg/ml	&	36µg/ml	solution	and10µl	 were	 injected	 into	 the	 system	 and	 the	chromatograms	were	recorded	to	assess	the	stability	of	the	sample.	
Photo	Stability	studies:	The	photochemical	stability	of	 the	 drug	 was	 also	 studied	 by	 exposing	 the	1600µg/ml	 Sofosbuvir	 	 &	 360µg/ml	 	 Ledipasvir		µg/ml	solution	to	UV	Light	by	keeping	the	beaker	in	UV	Chamber	for	1days	or	200	Watt	hours/m2	in	photo	stability	 chamber.	 For	 HPLC	 study,	 the	 resultant	solution	was	diluted	to	obtain	160µg/ml	&	36µg/ml	solutions	and	10µl	were	injected	into	the	system	and	the	 chromatograms	 were	 recorded	 to	 assess	 the	stability	of	sample.	
Neutral	Degradation	Studies:	Stress	testing	under	neutral	conditions	was	studied	by	refluxing	the	drug	in	water	for	1hrs	at	a	temperature	of	60º.	For	HPLC	study,	 the	 resultant	 solution	was	diluted	 to	160µg/	chromatograms	were	recorded	ml&36µg/ml	solution	and	10µl	were	 injected	 into	 the	 system	and	 the	 	 to	assess	the	stability	of	the	sample.	
Table 10: Degradation Data of Sofosbuvir 
S.NO	
Degra-
dation	
Condi-
tion	
%	Drug	
De-
graded	
Purity	
Angle	
Purity	
Thresh-
old	
1	 Acid	 4.21	 0.051	 0.296	
2	 Alkali	 3.96	 0.124	 0.252	
3	 Oxida-tion	 3.89	 0.159	 0.304	
4	 Thermal	 2.61	 0.197	 0.294	
5	 UV	 1.48	 0.133	 0.280	
6	 Water	 1.48	 0.044	 0.287	
Table 11: Degradation Data of Bromhexine S.NO	 Degrada-tion	Con-dition	 %	Drug	De-graded	 Purity	Angle	 Purity	Thresh-old	
1	 Acid	 4.62	 0.187	 0.320	
2	 Alkali	 4.22	 0.162	 0.587	
3	 Oxida-tion	 3.78	 0.171	 0.328	
4	 Thermal	 2.78	 0.197	 0.297	
5	 UV	 1.22	 0.130	 0.296	
6	 Water	 0.90	 0.123	 0.299	
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Regarding	the	pH	adjustment	in	mobile	phase	for	the	acid	and	base	degradation	studies	have	movement	in	retention	time	of	drugs.	But	due	to	neutralized	acid	sample	with	2N	Base	solution	and	base	sample	with	2N	Acid	solution	there	will	be	no	change	in	retention	time.	
CONCLUSION	A	 simple,	 Accurate,	 precise	method	 was	 developed	for	the	simultaneous	estimation	of	the	Sofosbuvir	and	Ledipasvir	 in	Tablet	dosage	form.	Retention	time	of	Sofosbuvir	 and	 Ledipasvir	 were	 found	 to	 be	 2.367	min	 and	 3.436	 min.	 %RSD	 of	 the	 Sofosbuvir	 and	Ledipasvir	 were	 and	 found	 to	 be	 0.6	 and	 0.5	respectively.	 %Recovery	 was	 obtained	 as	 99.61%	and	 99.80%	 for	 Sofosbuvir	 and	 Ledipasvir	respectively.	 LOD,	 LOQ	 values	 obtained	 from	regression	 equations	 of	 Sofosbuvir	 and	 Ledipasvir	were	 0.67,	 2.02	 and	 0.70,	 2.12	 respectively.	Regression	 equation	 of	 Sofosbuvir	 is	 y	 =	 4266.x	 +	7700,	and	y	=	4861.x	+	2656.of	Ledipasvir.	Retention	times	 were	 decreased	 and	 that	 run	 time	 was	decreased,	so	the	method	developed	was	simple	and	economical	 that	 can	 be	 adopted	 in	 regular	 Quality	control	test	in	Industries.				
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